Reducing distress and tobacco smoking in cancer survivors: a TDCS telehealth study

减少癌症幸存者的痛苦和吸烟:TDCS 远程医疗研究

基本信息

项目摘要

Project Summary/Abstract Cigarette smoking is the most prevalent cause of lung cancer, and also the strongest modifiable risk factor for cancer deaths among survivors. Unfortunately, the psychological distress associated with a cancer diagnosis makes smoking cessation particularly challenging for these patients. Distress itself is one of the core features of Koob & Volkow’s 3-stage model of addiction. Each of these stages is regulated by complementary brain circuits – which represent putative treatment targets. The long term goal of our research team is to develop an evidence- based brain stimulation treatment protocol for smoking cessation which is accessible, scalable, and an adjuvant to pharmacotherapy or psychotherapy among cancer survivors. Before embarking on a large multisite and multimodal clinical trial, however, it is critical to evaluate feasibility of delivering RS-tDCS to our target population (Aim 1) as well as estimated effect sizes on distress (Aim 2A) and smoking (Aim 2B). (Scientific Gap). Our team has developed and extensively validated a protocol for remotely supervised neuromodulation intervention which is delivered to participants at home and monitored by clinician during a telehealth visit. This remotely supervised technique utilizes transcranial direct current stimulation (RS-tDCS) and can be delivered safely via daily telehealth visits for extended treatment periods to provide cumulative benefit. Building on an established body of work, we seek to decrease distress among individuals with a prior cancer diagnosis and TUD via DLPFC tDCS. The goal of this proposal is to evaluate this technique as a feasible (Aim 1) tool to decrease distress and cigarette smoking (Aim 2) among this population. We propose a double-blind sham- controlled trial of a completely at-home intervention - RS-tDCS (DLFPC, 2.0 mA) paired with guided mindfulness meditation as a tool to decrease distress and smoking behavior among individuals with TUD. Eligible participants with a prior cancer diagnosis and TUD (n=46) will be randomized to active vs. sham tDCS for 20 daily (M-F) x 20 min sessions over one month, followed by 3 monthly follow up video visits. We hypothesize that active vs. sham tDCS will lead to greater reductions in distress and decrease smoking behaviors (Aim 2) by treatment end (primary) and through the 3 month follow up (secondary). The need for scalable, remote therapeutics which can be coupled with telehealth counseling techniques is more important than ever given the worldwide burden of COVID-19, including stay-at-home orders and an unprecedented acceleration in smoking and tobacco purchases. RS-tDCS as a tool to reduce distress and smoking behavior in people’s own homes represents a next-generation therapeutic approach– an important step forward for individuals struggling with a prior cancer diagnosis and current TUD, and is especially timely amidst the COVID-19 pandemic.
项目总结/摘要 吸烟是肺癌最常见的原因,也是最强的可改变的风险因素, 幸存者中的癌症死亡人数。不幸的是,癌症诊断带来的心理困扰 这使得戒烟对这些患者来说特别具有挑战性。痛苦本身就是 Koob & Koobow的成瘾三阶段模型。每一个阶段都是由互补的大脑回路调节的 - 其代表假定的治疗靶点。我们研究团队的长期目标是开发证据- 基于脑刺激的戒烟治疗方案,易于使用、可扩展且是一种辅助剂 癌症幸存者的药物治疗或心理治疗。在开始一个大型的多站点和 然而,多模式临床试验,关键是评估将RS-tDCS输送到我们的目标人群的可行性 (Aim 1)以及对痛苦(目标2A)和吸烟(目标2B)的估计效应量。(科学鸿沟)。 我们的团队已经开发并广泛验证了远程监督神经调节的协议 在远程保健访问期间,向在家的参与者提供并由临床医生监测的干预。这 远程监督技术利用经颅直流电刺激(RS-tDCS), 安全地通过每日远程保健访问延长治疗期,以提供累积效益。建立在 建立的工作机构,我们寻求减少个人与先前的癌症诊断, TUD通过DLPFC tDCS。本提案的目的是评估该技术作为一种可行的(目标1)工具, 减少这一人群的痛苦和吸烟(目标2)。我们提出一个双盲的假手术- 完全在家干预的对照试验- RS-tDCS(DLFPC,2.0 mA)与引导正念配对 冥想作为减少TUD患者痛苦和吸烟行为的工具。合资格参与者 既往诊断为癌症且TUD的患者(n=46)将随机分为活性tDCS组与假tDCS组,每日20次(M-F)x 在一个月内进行20分钟的会话,然后每月进行3次随访视频访视。我们假设,积极与。 到治疗结束时,假tDCS将导致更大程度的痛苦减轻和吸烟行为减少(目标2) (主要)和3个月随访(次要)。 对可扩展的远程治疗的需求,可以与远程健康咨询技术相结合, 考虑到COVID-19的全球负担,包括居家订单和 吸烟和烟草购买空前加速。RS-tDCS作为一种工具,以减少痛苦和 在人们自己家里吸烟的行为代表了下一代的治疗方法-一个重要的步骤 对于那些与先前的癌症诊断和当前的TUD作斗争的人来说,这是非常及时的, COVID-19大流行。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Merideth A. Addicott其他文献

Nicotine withdrawal induces neural and behavioral deficits in reward processing
尼古丁戒断会导致奖励处理中的神经和行为缺陷
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jason A. Oliver;D. Evans;Merideth A. Addicott;T. Brandon;D. Drobes
  • 通讯作者:
    D. Drobes
The Effects of Dietary Caffeine Use and Abstention on Blood Oxygen Level-Dependent Activation and Cerebral Blood Flow.
膳食咖啡因的使用和戒断对血氧水平依赖性激活和脑血流量的影响。
  • DOI:
    10.1089/jcr.2011.0027
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Merideth A. Addicott;A. Peiffer;P. Laurienti
  • 通讯作者:
    P. Laurienti
Erratum to: Smoking withdrawal is associated with increases in brain activation during decision making and reward anticipation: A preliminary study
  • DOI:
    10.1007/s00213-011-2531-x
  • 发表时间:
    2011-10-18
  • 期刊:
  • 影响因子:
    3.300
  • 作者:
    Merideth A. Addicott;David A. A. Baranger;Rachel V. Kozink;Moria J. Smoski;Gabriel S. Dichter;F. Joseph McClernon
  • 通讯作者:
    F. Joseph McClernon

Merideth A. Addicott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Merideth A. Addicott', 18)}}的其他基金

Reducing distress and tobacco smoking in cancer survivors: a TDCS telehealth study
减少癌症幸存者的痛苦和吸烟:TDCS 远程医疗研究
  • 批准号:
    10680370
  • 财政年份:
    2022
  • 资助金额:
    $ 25.01万
  • 项目类别:
Effects of ketamine on tobacco use disorder - Resubmission
氯胺酮对烟草使用障碍的影响 - 重新提交
  • 批准号:
    10371688
  • 财政年份:
    2022
  • 资助金额:
    $ 25.01万
  • 项目类别:
Effects of ketamine on tobacco use disorder - Resubmission
氯胺酮对烟草使用障碍的影响 - 重新提交
  • 批准号:
    10625289
  • 财政年份:
    2022
  • 资助金额:
    $ 25.01万
  • 项目类别:
Neural correlates of distress tolerance in tobacco addiction
烟草成瘾中痛苦耐受性的神经相关性
  • 批准号:
    10496770
  • 财政年份:
    2021
  • 资助金额:
    $ 25.01万
  • 项目类别:
Distress Tolerance and Smoking Cessation
痛苦耐受力和戒烟
  • 批准号:
    10405652
  • 财政年份:
    2021
  • 资助金额:
    $ 25.01万
  • 项目类别:
Distress Tolerance and Smoking Cessation
痛苦耐受力和戒烟
  • 批准号:
    10521970
  • 财政年份:
    2021
  • 资助金额:
    $ 25.01万
  • 项目类别:
Distress Tolerance and Smoking Cessation
痛苦耐受力和戒烟
  • 批准号:
    10624427
  • 财政年份:
    2021
  • 资助金额:
    $ 25.01万
  • 项目类别:
Distress Tolerance and Smoking Cessation
痛苦耐受力和戒烟
  • 批准号:
    10166818
  • 财政年份:
    2019
  • 资助金额:
    $ 25.01万
  • 项目类别:
Longitudinal Investigation of TMS as a Tool to Improve Alcohol Treatment Outcomes
TMS 作为改善酒精治疗结果工具的纵向调查
  • 批准号:
    10844805
  • 财政年份:
    2019
  • 资助金额:
    $ 25.01万
  • 项目类别:
Translational approaches to TMS treatment development for smoking
吸烟 TMS 治疗开发的转化方法
  • 批准号:
    10152574
  • 财政年份:
    2019
  • 资助金额:
    $ 25.01万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 25.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了